Skip to main content
. 2012 Sep 20;7(9):e45587. doi: 10.1371/journal.pone.0045587

Figure 2. ON-time and quality of ON-time.

Figure 2

A. UWA-101 (3, 6, 10 mg/kg), when co-administered with L-DOPA, significantly increased duration of ON-time compared to L-DOPA/ vehicle treatment. Following administration of L-DOPA/ vehicle, marmosets had a mean duration of ON-time of 221.8±19.0 min. Combining L-DOPA with UWA-101 3 or 6 mg/kg both led to an additional 62 min of ON-time, while UWA-101 10 mg/kg led to an additional 72.2 min of ON-time (all P<0.05). B. UWA-101 (1, 3, 6, 10 mg/kg), in combination with L-DOPA, did not alter duration of ON-time with dyskinesia. Following administration of L-DOPA/ vehicle, the mean duration of ON-time with dyskinesia was 190.0±26.9 min. This was not significantly modified when UWA-101 was added to L-DOPA (all P>0.05). C. UWA-101 (1, 3, 6, 10 mg/kg), in combination with L-DOPA, significantly increased duration of ON-time without dyskinesia. The administration of L-DOPA/ vehicle led to a mean duration of ON-time without dyskinesia of 30.0±15.8 min. When co-administered with L-DOPA, UWA-101 (1, 3, 6, 10 mg/kg) , increased duration of ON-time without dyskinesia by 64 min, 80 min, 64 min and 90 min, respectively (P<0.05 for UWA-101 1 and 6 mg/kg, and P<0.01 for UWA-101 3 and 10 mg/kg). D. UWA-101 (10 mg/kg) significantly extended duration of ON-time without disabling dyskinesia, when combined with L-DOPA. Following L-DOPA/ vehicle treatment, duration of ON-time without disabling dyskinesia was 152.0±32.1 min. The co-administration of UWA-101 10 mg/kg added 94 min (P<0.01). *: P<0.05; **: P<0.01. Data are expressed as the mean ± SEM.